Overexpressed HDGF as an independent prognostic factor is involved in poor prognosis in Chinese patients with liver cancer

Diagnostic Pathology

Volumn 5, Issue 1, 2010, Pages

  Zhou, Yanyan ^a   Zhou, Nanxiang ^a   Fang, Weiyi ^b   Huo, Jirong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATOMA DERIVED GROWTH FACTOR; HEPATOMA-DERIVED GROWTH FACTOR; SIGNAL PEPTIDE; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ANIMAL; ARTICLE; ASIAN; BAGG ALBINO MOUSE; CANCER INVASION; CANCER STAGING; CELL MOTION; CELL PROLIFERATION; CELL STRAIN HEPG2; CHINA; DRUG SCREENING; ETHNOLOGY; FEMALE; GENETIC TRANSFECTION; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MOUSE; NUDE MOUSE; PROGNOSIS; RNA INTERFERENCE; TIME; TUMOR VOLUME; UPREGULATION;

ADOLESCENT; ADULT; AGED; ANIMALS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; CELL PROLIFERATION; CHINA; FEMALE; HEP G2 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RNA INTERFERENCE; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 77956604953     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-5-58     Document Type: Article

References (37)

1. Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma--epidemiological trends and risk factors. Dig Dis 2009, 27:80-92.
2. Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta 2001, 313:15-19. 10.1016/S0009-8981(01)00644-1, 11694234.
3. Blum HE, Spangenberg HC. Hepatocellular carcinoma: an update. Arch Iran Med 2007, 10:361-371.
4. Nakamura H, Izumoto Y, Kambe H, Kuroda T, Mori T, Kawamura K, Yamamoto H, Kishimoto T. Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J Biol Chem 1994, 269:25143-25149.
5. Nakamura H, Kambe H, Egawa T, Kimura Y, Ito H, Hayashi E, Yamamoto H, Sato J, Kishimoto S. Partial purification and characterization of human hepatoma-derived growth factor. Clin Chim Acta 1989, 183:273-284. 10.1016/0009-8981(89)90361-6, 2553304.
6. Everett AD, Stoops T, McNamara CA. Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells. J Biol Chem 2001, 276:37564-37568. 10.1074/jbc.M105109200, 11481329.
7. Enomoto H, Yoshida K, Kishima Y, Kinoshita T, Yamamoto M, Everett AD, Miyajima A, Nakamura H. Hepatoma-derived growth factor is highly expressed in developing liver and promotes fetal hepatocyte proliferation. Hepatology 2002, 36:1519-1527.
8. Okuda Y, Nakamura H, Yoshida K, Enomoto H, Uyama H, Hirotani T, Funamoto M, Ito H, Everett AD, Hada T, Kawase I. Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Sci 2003, 94:1034-1041. 10.1111/j.1349-7006.2003.tb01397.x, 14662017.
9. Everett AD, Narron JV, Stoops T, Nakamura H, Tucker A. Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor. Am J Physiol Lung Cell Mol Physiol 2004, 286:L1194-1201. 10.1152/ajplung.00427.2003, 14751852.
10. Matsuyama A, Inoue H, Shibuta K, Tanaka Y, Barnard GF, Sugimachi K, Mori M. Hepatoma-derived growth factor is associated with reduced sensitivity to irradiation in esophageal cancer. Cancer Res 2001, 61:5714-5717.
11. Everett AD. Identification, cloning, and developmental expression of hepatoma-derived growth factor in the developing rat heart. Dev Dyn 2001, 222:450-458. 10.1002/dvdy.1204, 11747079.
12. Oliver JA, Al-Awqati Q. An endothelial growth factor involved in rat renal development. J Clin Invest 1998, 102:1208-1219. 10.1172/JCI785, 509104, 9739055.
13. Savola S, Klami A, Tripathi A, Niini T, Serra M, Picci P, Kaski S, Zambelli D, Scotlandi K, Knuutila S. Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer 2009, 9:17. 10.1186/1471-2407-9-17, 2633345, 19144156.
14. Chang KC, Tai MH, Lin JW, Wang CC, Huang CC, Hung CH, Chen CH, Lu SN, Lee CM, Changchien CS, Hu TH. Hepatoma-derived growth factor is a novel prognostic factor for gastrointestinal stromal tumors. Int J Cancer 2007, 121:1059-1065. 10.1002/ijc.22803, 17487837.
15. Yoshida K, Tomita Y, Okuda Y, Yamamoto S, Enomoto H, Uyama H, Ito H, Hoshida Y, Aozasa K, Nagano H, Sakon M, Kawase I, Monden M, Nakamura H. Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann Surg Oncol 2006, 13:159-167. 10.1245/ASO.2006.11.035, 16411141.
16. Iwasaki T, Nakagawa K, Nakamura H, Takada Y, Matsui K, Kawahara K. Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer. Oncol Rep 2005, 13:1075-1080.
17. Ren H, Tang X, Lee JJ, Feng L, Everett AD, Hong WK, Khuri FR, Mao L. Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J Clin Oncol 2004, 22:3230-3237. 10.1200/JCO.2004.02.080, 15310766.
18. Yamamoto S, Tomita Y, Hoshida Y, Morii E, Yasuda T, Doki Y, Aozasa K, Uyama H, Nakamura H, Monden M. Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma. Ann Surg Oncol 2007, 14:2141-2149. 10.1245/s10434-007-9369-9, 17473954.
19. Uyama H, Tomita Y, Nakamura H, Nakamori S, Zhang B, Hoshida Y, Enomoto H, Okuda Y, Sakon M, Aozasa K, Kawase I, Hayashi N, Monden M. Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res 2006, 12:6043-6048. 10.1158/1078-0432.CCR-06-1064, 17062679.
20. Fang W, Li X, Jiang Q, Liu Z, Yang H, Wang S, Xie S, Liu Q, Liu T, Huang J, Xie W, Li Z, Zhao Y, Wang E, Marincola FM, Yao K. Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med 2008, 6:32. 10.1186/1479-5876-6-32, 2443113, 18570662.
21. Tu L, Liu Z, He X, He Y, Yang H, Jiang Q, Xie S, Xiao G, Li X, Yao K, Fang W. Over-expression of eukaryotic translation initiation factor 4 gamma 1 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma. Mol Cancer 2010, 9:78. 10.1186/1476-4598-9-78, 2873436, 20398343.
22. Liu Z, Li L, Yang Z, Luo W, Li X, Yang H, Yao K, Wu B, Fang W. Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer 2010, 10:-270.
23. Xie SM, Fang WY, Liu Z, Wang SX, Li X, Liu TF, Xie WB, Yao KT. Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med 2008, 4;6:55.
24. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006, 6:674-687. 10.1038/nrc1934, 16929323.
25. Chang Q, Chen J, Beezhold KJ, Castranova V, Shi X, Chen F. JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma. Mol Cancer 2009, 8:64. 10.1186/1476-4598-8-64, 2732591, 19686584.
26. Wei W, Chua MS, Grepper S, So SK. Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells. Mol Cancer 2009, 8:76. 10.1186/1476-4598-8-76, 2759906, 19778454.
27. Austinat M, Dunsch R, Wittekind C, Tannapfel A, Gebhardt R, Gaunitz F. Correlation between beta-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma. Mol Cancer 2008, 7:21. 10.1186/1476-4598-7-21, 2287186, 18282277.
28. Liu J, Ahiekpor A, Li L, Li X, Arbuthnot P, Kew M, Feitelson MA. Increased expression of ErbB-2 in liver is associated with hepatitis B × antigen and shorter survival in patients with liver cancer. Int J Cancer 2009, 125(8):1894-1901. 10.1002/ijc.24580, 2745322, 19610068.
29. Csepregi A, Ebert MP, Rocken C, Schneider-Stock R, Hoffmann J, Schulz HU, Roessner A, Malfertheiner P. Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma. BMC Cancer 2010, 10:317. 10.1186/1471-2407-10-317, 2927998, 20569442.
30. Tung EK, Wong CM, Yau TO, Lee JM, Ching YP, Ng IO. HAI-2 is epigenetically downregulated in human hepatocellular carcinoma, and its Kunitz domain type 1 is critical for anti-invasive functions. Int J Cancer 2009, 124:1811-1819. 10.1002/ijc.24115, 19107935.
31. Chan DW, Lee JM, Chan PC, Ng IO. Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma cells. Int J Cancer 2008, 123:1043-52. 10.1002/ijc.23634, 18553387.
32. Everett AD, Bushweller J. Hepatoma derived growth factor is a nuclear targeted mitogen. Curr Drug Targets 2003, 4:367-371. 10.2174/1389450033490975, 12816346.
33. Kishima Y, Yamamoto H, Izumoto Y, Yoshida K, Enomoto H, Yamamoto M, Kuroda T, Ito H, Yoshizaki K, Nakamura H. Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals. J Biol Chem 2002, 277:10315-10322. 10.1074/jbc.M111122200, 11751870.
34. Mao J, Xu Z, Fang Y, Wang H, Xu J, Ye J, Zheng S, Zhu Y. Hepatoma-derived growth factor involved in the carcinogenesis of gastric epithelial cells through promotion of cell proliferation by Erk1/2 activation. Cancer Sci 2008, 99:2120-2127. 10.1111/j.1349-7006.2008.00928.x, 18823380.
35. Zhou Z, Yamamoto Y, Sugai F, Yoshida K, Kishima Y, Sumi H, Nakamura H, Sakoda S. Hepatoma-derived growth factor is a neurotrophic factor harbored in the nucleus. J Biol Chem 2004, 279:27320-27326. 10.1074/jbc.M308650200, 15140875.
36. Zhang J, Ren H, Yuan P, Lang W, Zhang L, Mao L. Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res 2006, 66:18-23. 10.1158/0008-5472.CAN-04-3905, 16397209.
37. Ren H, Chu Z, Mao L. Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer. Mol Cancer Ther 2009, 8:1106-1112.